Press Releases keyboard_arrow_down
Media Coverage keyboard_arrow_down
Events keyboard_arrow_down
Blog keyboard_arrow_down
Webinars keyboard_arrow_down
Brochures keyboard_arrow_down

Media Relations

Avery Dennison
Medical Solutions

Bob Giuliano
+1 (610) 328-1051

Kate Franco
+1 (312) 206-1037


Quick-Med Technologies
J. Ladd Greeno, CEO
(888) 835.2211 Ext 102


Stonegate Securities, Inc
(investor/media contact)
Casey Stegman
(214) 987-4121

Avery Dennison
Investor Relations

Eric M. Leeds
+1 (626) 304-2029

PDF Version

Avery Dennison Medical Solutions and Quick-Med Technologies Successfully Develop New, High-Performance Antimicrobial Adhesive

Avery Dennison Medical Solutions Expands Technology Platform; Licenses NIMBUS® from Quick-Med

CHICAGO and GAINESVILLE, Fla. – April 12, 2011 – Avery Dennison Medical Solutions, a division of Avery Dennison Corporation (NYSE: AVY) and a global leader in pressure-sensitive adhesive technologies for medical applications, in partnership with Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that develops innovative technologies for healthcare and consumer markets, today announced the completion of a license agreement for Quick-Med’s NIMBUS® technology. The announcement comes after Avery Dennison Medical Solutions’ successful development of a new antimicrobial adhesive featuring NIMBUS technology that can be incorporated into a variety of medical device applications, including surgical, wound care and vascular access products. The antimicrobial adhesive can be effective across multiple organisms even in the presence of large amounts of serum and body fluids.

“We are advancing our antimicrobial technology platform to provide innovative solutions that answer the needs of medical device providers and patients worldwide,” said Howard Kelly, Vice President and General Manager, Avery Dennison Medical Solutions. “The success of our partnership with Quick-Med is a key component of our progress in this segment. We look forward to expanding our antimicrobial offerings and accelerating our growth now that the license agreement is in place.”

Under a joint development agreement initiated in April 2009, the two companies worked in close collaboration to incorporate Quick-Med’s proprietary NIMBUS antimicrobial technology into Avery Dennison Medical Solutions’ adhesive technologies for medical device applications. NIMBUS is non-toxic, non-leaching and non-depleting, and is designed to eliminate the risk of bacterial resistance issues.

“Successful development of the antimicrobial adhesive and completion of the license agreement with Avery Dennison Medical Solutions, an industry leader and innovator, further validates the potential of Quick-Med’s technologies for a range of applications,” said J. Ladd Greeno, CEO of Quick-Med Technologies. “This valuable partnership will continue to leverage the combination of Avery Dennison Medical Solutions’ inventive adhesive technologies with our highly effective, non-toxic, long-lasting, non-leaching and affordable antimicrobial protection, for the multi-billion dollar global medical adhesives market.”





© 2011 Avery Dennison Corporation, All Rights Reserved. Avery Dennison® is a registered trademark of Avery Dennison Corporation. Avery and all other Avery Dennison brands, product names and codes or service programs are trademarks of Avery Dennison Corporation. Avery Dennison Medical Products, a division of Avery Dennison Corporation.

© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at

© 2016 Avery Dennison Corporation, All Rights Reserved.

Various trademarks and trade names are used herein and are the property of their respective owners.